Cargando…

DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial

Veliparib combined with carboplatin (VC) was an experimental regimen evaluated in the biomarker-rich neoadjuvant I-SPY 2 trial for breast cancer. VC showed improved efficacy in the triple negative signature. However, not all triple negative patients achieved pathologic complete response and some HR+...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wolf, Denise M., Yau, Christina, Sanil, Ashish, Glas, Annuska, Petricoin, Emanuel, Wulfkuhle, Julia, Severson, Tesa M., Linn, Sabine, Brown-Swigart, Lamorna, Hirst, Gillian, Buxton, Meredith, DeMichele, Angela, Hylton, Nola, Symmans, Fraser, Yee, Doug, Paoloni, Melissa, Esserman, Laura, Berry, Don, Rugo, Hope, Olopade, Olufunmilayo, van ‘t Veer, Laura
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572474/ https://www.ncbi.nlm.nih.gov/pubmed/28948212 http://dx.doi.org/10.1038/s41523-017-0025-7

Ejemplares similares

Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trial
por: Wolf, Denise M., et al.
Publicado: (2020)

Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL
por: Olshen, Adam, et al.
Publicado: (2017)

Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2(+) breast cancer in the adaptively randomized I-SPY2 trial
por: Clark, Amy S., et al.
Publicado: (2021)

Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial
por: Parker, Barbara A., et al.
Publicado: (2023)

Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors
por: Bartelink, Imke H., et al.
Publicado: (2017)

Clinically Meaningful Tumor Reduction Rates Vary by Prechemotherapy MRI Phenotype and Tumor Subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
por: Mukhtar, Rita A., et al.
Publicado: (2013)

Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
por: Esserman, Laura J., et al.
Publicado: (2011)

The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting
por: Severson, Tesa M., et al.
Publicado: (2017)

Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk
por: Magbanua, Mark Jesus M., et al.
Publicado: (2021)

Pretreatment vitamin D level and response to neoadjuvant chemotherapy in women with breast cancer on the I-SPY trial (CALGB 150007/150015/ACRIN6657)
por: Clark, Amy S, et al.
Publicado: (2014)

Impact of MRI Protocol Adherence on Prediction of Pathological Complete Response in the I-SPY 2 Neoadjuvant Breast Cancer Trial
por: Onishi, Natsuko, et al.
Publicado: (2020)

Effect of MR Imaging Contrast Thresholds on Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes: A Subgroup Analysis of the ACRIN 6657/I-SPY 1 TRIAL
por: Li, Wen, et al.
Publicado: (2016)

Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer
por: Lang, Julie E., et al.
Publicado: (2022)

Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer
por: Yee, Douglas, et al.
Publicado: (2021)

PRoBE the cloud toolkit: finding the best biomarkers of drug response within a breast cancer clinical trial
por: O'Grady, Nicholas, et al.
Publicado: (2021)

Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes
por: Yu, Katharine, et al.
Publicado: (2023)

Profile of veliparib and its potential in the treatment of solid tumors
por: Wagner, Lars M
Publicado: (2015)

Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma
por: Jue, Toni Rose, et al.
Publicado: (2017)

Radiomic tumor phenotypes augment molecular profiling in predicting recurrence free survival after breast neoadjuvant chemotherapy
por: Chitalia, Rhea, et al.
Publicado: (2023)

Veliparib Is an Effective Radiosensitizing Agent in a Preclinical Model of Medulloblastoma
por: Buck, Jessica, et al.
Publicado: (2021)

Effect of the PARP inhibitor veliparib on germ cell tumor cell lines
por: Schmidtova, Silvia, et al.
Publicado: (2022)

Expert tumor annotations and radiomics for locally advanced breast cancer in DCE-MRI for ACRIN 6657/I-SPY1
por: Chitalia, Rhea, et al.
Publicado: (2022)

Blocking PARP activity with the inhibitor veliparib enhances radiotherapy sensitivity in endometrial carcinoma
por: Wang, Jing, et al.
Publicado: (2022)

Synthesis of Veliparib Prodrugs and Determination of Drug-Release-Dependent PARP-1 Inhibition
por: Borgini, Matteo, et al.
Publicado: (2023)

SpiNNTools: The Execution Engine for the SpiNNaker Platform
por: Rowley, Andrew G. D., et al.
Publicado: (2019)

Neoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferation
por: Severson, Tesa M., et al.
Publicado: (2016)

MDB-36. SONIDEGIB, GANT61, AND VELIPARIB TREATMENT BOTH ALONE AND IN COMBINATION INCREASES RADIATION SENSITIVITY IN PEDIATRIC SONIC HEDGEHOG MEDULLOBLASTOMA
por: Price, Laura, et al.
Publicado: (2023)

Spy&Go purification of SpyTag-proteins using pseudo-SpyCatcher to access an oligomerization toolbox
por: Khairil Anuar, Irsyad N. A., et al.
Publicado: (2019)

Spying on the environment.
Publicado: (1995)

The virus spy
por: Hoag, Hannah
Publicado: (2009)

Effect of Imaging Parameter Thresholds on MRI Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes
por: Lo, Wei-Ching, et al.
Publicado: (2016)

Catching a SPY: Using the SpyCatcher-SpyTag and Related Systems for Labeling and Localizing Bacterial Proteins
por: Hatlem, Daniel, et al.
Publicado: (2019)

SpyDisplay: A versatile phage display selection system using SpyTag/SpyCatcher technology
por: Kellmann, Sarah-Jane, et al.
Publicado: (2023)

Development of SpyTag/SpyCatcher-Bacmid Expression Vector System (SpyBEVS) for Protein Bioconjugations Inside of Silkworms
por: Xu, Jian, et al.
Publicado: (2019)

Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma
por: Gabrielson, Andrew, et al.
Publicado: (2015)

An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer
por: Stringer-Reasor, Erica M., et al.
Publicado: (2021)

SpyTag/SpyCatcher Cyclization Enhances the Thermostability of Firefly Luciferase
por: Si, Meng, et al.
Publicado: (2016)

Current Landscape of Breast Cancer Imaging and Potential Quantitative Imaging Markers of Response in ER-Positive Breast Cancers Treated with Neoadjuvant Therapy
por: Jones, Ella F., et al.
Publicado: (2020)

The spy that went into the cold
Publicado: (1998)

Five spy novels
Publicado: (1962)

Cannot write session to /tmp/vufind_sessions/sess_uignf39tq64k8snimvh9vsd2fj